Somewhat off topic but related to Generex/Olaregen
Post# of 36568
(Total Views: 886)
Posted On: 06/05/2020 8:49:56 PM
Somewhat off topic but related to Generex/Olaregen. The company who owned Excellagen, Taxus Cardium went dark like Generex. Hasn't kept up their filings. They changed their name to Gene Biotherapeutics a while back but kept the CRXM stock symbol. Somewhere in there they sold most of the Excellagen rights to Olaregen. I believe they are still owed money and royalty payments from Excellagen sales. They just announced an investment by a guy who owns a pharma company based in Jersey. I have kept in touch with CRXM's CEO, Chris Reinhard. He plans to bring the companies financials up to date and is planning on continuing trials on their genetic heart technology platform "Generx"
LOL, that is too funny). Unfortunately, the investment included the potential to dilute the common shares so I don't know what will happen to the PPS if they have to sell shares to raise money to fund the new trial. I have owned shares for long time so I am thrilled something is happening although I consider my investment a complete loss until proven otherwise. The trading volume is pathetic and has been down on the news so the dilution may be a concern. Anyway, the pharma company investor does a couple hundred million in revenue per year so I am told by an individual shareholder who owns 14% (confirmed by SEC filing) of the common. Between his shares, two of his friends and myself we control 22% plus of the common for now. Insiders have about 12% if yahoo is accurate. Anyway, it is a slow Friday night so I thought I would share given the olaregen/excellagen connection. I am not recommending anyone buy shares.
LOL, that is too funny). Unfortunately, the investment included the potential to dilute the common shares so I don't know what will happen to the PPS if they have to sell shares to raise money to fund the new trial. I have owned shares for long time so I am thrilled something is happening although I consider my investment a complete loss until proven otherwise. The trading volume is pathetic and has been down on the news so the dilution may be a concern. Anyway, the pharma company investor does a couple hundred million in revenue per year so I am told by an individual shareholder who owns 14% (confirmed by SEC filing) of the common. Between his shares, two of his friends and myself we control 22% plus of the common for now. Insiders have about 12% if yahoo is accurate. Anyway, it is a slow Friday night so I thought I would share given the olaregen/excellagen connection. I am not recommending anyone buy shares.
(1)
(0)